AC-262536 is a selective nonsteroidal androgen receptor modulator (SARM) with beneficial anabolic effects. AC-262536 has potent agonist activity against androgen receptors with affinity in the low nanomolar range (1-10 nM). It is another novel drug put forth by Acadia, just like ACP-105. It is a SARM by design, as it selectively binds to the androgen receptor, just like all the other SARMs. AC-262536 came into light in 2007 and even though 13 years have passed, little research has been done on this compound.
Testosterone Suppression: AC-262536 will suppress your natural testosterone levels. Compared to other SARMs, this suppression of testosterone is rather mild and similar to that of Ostarine and Andarine. Testosterone suppression can manifest in the following symptoms: Lethargy, Lack of motivation, Decreased libido, Weaker erections, Testicular pain, and Testicular atrophy.
AC-262536 will cause dyslipidemia. Your HDL will decrease, and your LDL will increase during an AC-262 cycle. The extent of this side effect can be compared to that of similarly strong SARMs.
The following side effects can happen to anyone who alters their endocrine balance, regardless of whether they’re taking AC-262 or something else: Gynecomastia: men who had pubertal gyno are at risk of redeveloping it if they take AC-262536; Hair shedding (temporary and completely reversible); Insomnia.
